Effects of early luteal phase vaginal progesterone supplementation on the outcome of in-vitro fertilization and embryo transfer
Phase 2
Completed
- Conditions
- infertilityReproductive Health and Childbirth - Fertility including in vitro fertilisation
- Registration Number
- ACTRN12608000200381
- Lead Sponsor
- The Chinese University of Hong Kong
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Female
- Target Recruitment
- 196
Inclusion Criteria
women undergoing the treatment of in-vitro fertilization and embryo transfer, with HCG administration as the standard luteal phase support
Exclusion Criteria
age = 40 year-old
use of vaginal progesterone for luteal phase support because of risk of ovarian hyperstimulation syndrome
distorted uterine cavity, e.g. due to submucosal fibroids or uterine anomalies
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method